Curative Biotechnology, Inc. (CUBT)
OTCMKTS · Delayed Price · Currency is USD
0.7500
-0.1500 (-16.67%)
At close: Sep 4, 2026
Curative Biotechnology Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 0.03 | 0.02 | 0.06 | 0.06 | 0.67 | 0.16 |
Cash & Short-Term Investments | 0.03 | 0.02 | 0.06 | 0.06 | 0.67 | 0.16 |
Cash Growth | - | -65.36% | -3.87% | -91.25% | 317.33% | - |
Other Receivables | - | - | 0.12 | - | 0.03 | - |
Receivables | - | - | 0.12 | - | 0.03 | - |
Prepaid Expenses | 0.09 | 0.16 | 0.43 | - | 0.06 | 1.9 |
Other Current Assets | - | - | - | - | - | 0.07 |
Total Current Assets | 0.12 | 0.18 | 0.6 | 0.06 | 0.75 | 2.13 |
Property, Plant & Equipment | 0 | 0 | 0.01 | 0.01 | 0.01 | 0 |
Other Intangible Assets | 1.33 | 1.35 | 1.42 | 1.51 | 1.56 | 0.14 |
Long-Term Deferred Charges | 0.69 | 0.66 | 0.57 | 0.49 | 0.09 | - |
Total Assets | 2.14 | 2.19 | 2.6 | 2.06 | 2.41 | 2.27 |
Liabilities
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 4.54 | 4.13 | 3.49 | 3.43 | 0.73 | 0.1 |
Short-Term Debt | 3.48 | 2.94 | 2.26 | 1.12 | - | 0.56 |
Other Current Liabilities | - | - | - | 0.04 | 0 | 0.01 |
Total Current Liabilities | 8.02 | 7.06 | 5.75 | 4.6 | 0.73 | 0.66 |
Total Liabilities | 8.02 | 7.06 | 5.75 | 4.6 | 0.73 | 0.66 |
Shareholders' Equity
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0.11 | 0.09 | 0.09 | 0.06 | 0 | 0 |
Additional Paid-In Capital | 38.5 | 36.79 | 34.99 | 29.81 | 10.56 | 3.58 |
Retained Earnings | -44.48 | -41.76 | -38.23 | -32.41 | -26.92 | -8.1 |
Total Common Equity | -5.88 | -4.88 | -3.15 | -2.54 | -16.36 | -4.52 |
Shareholders' Equity | -5.88 | -4.87 | -3.14 | -2.54 | 1.68 | 1.61 |
Total Liabilities & Equity | 2.14 | 2.19 | 2.6 | 2.06 | 2.41 | 2.27 |
Additional Metrics
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 3.48 | 2.94 | 2.26 | 1.12 | - | 0.56 |
Net Cash (Debt) | -3.44 | -2.92 | -2.2 | -1.07 | 0.67 | -0.4 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.51 | -0.48 | -0.50 | -0.28 | 0.20 | -0.18 |
Filing Date Shares Outstanding | 7.15 | 6.13 | 6.02 | 3.81 | 3.81 | 3.63 |
Total Common Shares Outstanding | 7.15 | 6.13 | 6.02 | 3.81 | 3.8 | 2.22 |
Working Capital | -7.9 | -6.88 | -5.14 | -4.54 | 0.02 | 1.47 |
Book Value Per Share | -0.82 | -0.80 | -0.52 | -0.67 | -4.30 | -2.04 |
Tangible Book Value | -7.21 | -6.22 | -4.57 | -4.05 | -17.92 | -4.66 |
Tangible Book Value Per Share | -1.01 | -1.02 | -0.76 | -1.06 | -4.71 | -2.10 |